GlassScriptPhysician profile
Mohan M Menon
NPI 1851491377
$6,186.29
in general payments reported to CMS, 2019-2025
26 companies · $96.00 in 2025
The $96.00 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,070 · 2020: $1,196 · 2021: $1,693 · 2022: $1,131 · 2025: $96.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $96.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $96.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,592.51 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $1,026.06 | 2019-2022 | |
| Csl Behring | $579.80 | 2019-2025 | Andembry |
| Genzyme Corporation | $542.89 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $378.63 | 2020-2022 | |
| Pfizer INC. | $276.86 | 2019-2022 | |
| Abbvie INC. | $183.72 | 2021-2022 | |
| Biocryst US Sales Co., LLC | $180.99 | 2021-2022 | |
| Genentech USA, INC. | $165.56 | 2019 | |
| Kaleo, INC. | $145.33 | 2019-2021 | |
| Pharming Healthcare, INC. | $123.52 | 2019-2020 | |
| Amgen INC. | $122.09 | 2021 | |
| Aimmune Therapeutics, INC. | $121.57 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $108.58 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $100.11 | 2019-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $97.44 | 2019-2020 | |
| Shire North American Group INC | $92.57 | 2019 | |
| Grifols USA, LLC | $89.11 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $58.67 | 2019 | |
| Sanofi-Aventis U.S. LLC | $51.25 | 2020 | |
| Optinose US, INC. | $31.14 | 2019-2020 | |
| Octapharma USA, INC. | $30.54 | 2019 | |
| Alk-Abello, INC | $30.47 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $23.07 | 2022 | |
| Biocryst Pharmaceuticals, INC. | $19.58 | 2020 | |
| Merck Sharp & Dohme LLC | $14.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohan Menon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.